Univo IRB Launches First-of-Its-Kind Electronic IRB Submission Portal, OneVerse™
26 Junio 2024 - 7:00AM
Business Wire
Univo IRB, a next generation institutional review board (IRB),
announced the launch of OneVerse™ — the industry’s first
purpose-built, electronic platform that modernizes the IRB
experience. OneVerse is designed around user experience and
transparency, facilitating seamless study submission, secure
document sharing, and direct communication across all research
study stakeholders.
“Univo IRB team members have worked on all sides of clinical
research,” said Heather Fitzgerald, Univo IRB’s VP of Operations.
“We’ve witnessed IRB technology slowing down the review processes
with lengthy forms, limited transparency, and poor communication.
We took our firsthand experience and designed a modern and
user-friendly platform. OneVerse will completely change how users
think about IRB submission and allow research organizations, sites,
and sponsors to get to study startup faster.”
OneVerse was developed with industry expertise in artificial
intelligence (AI) combined with a user centric design process.
“When combined with Univo’s extensive IRB operational and
regulatory expertise, OneVerse changes the way customers and
patients will engage with an IRB,” said Julie Blasingim, Univo
IRB’s CEO. “Univo’s focus on enabling highly efficient IRB
processes and connecting patients with researchers drove our system
design to streamline submissions and foster transparency,
benefiting multiple research stakeholders.”
OneVerse features include the ability for users to access a
searchable review of submission statuses and action items; dynamic
generation of processes, forms, and requests; simple collaboration
allowing study teams to access documentation, amendments, and
updates; and tailored submission guidance and IRB resources
available 24/7. Compared to other IRB tools and processes, the
platform creates many efficiencies by using AI to automate
administrative tasks as part of an overall enhanced end user
experience. New functionality will continue to be released
throughout 2024 helping to establish OneVerse as the new standard
in IRB innovation technology.
Visit Univo-Group.com/OneVerse for more information or to
request a demo.
About Univo IRB
Univo IRB, formerly Principal IRB, is a next generation
institutional review board (IRB) specializing in the ethical review
of Phase I-IV pharmaceutical, device, biologic, behavioral, and
psycho-social research. We offer agile study approaches, expert
solutions powered by industry-leading study technology, and a
service-first approach. Univo IRB holds accreditation through the
Association for the Accreditation of Human Research Protection
Programs (AAHRPP). With support from senior advisors and 60+ years
of industry experience, Univo IRB guides studies to approval while
respecting the rights and welfare of patients every step of the
way.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240626308687/en/
Holli Kroeker SCORR Marketing 308-338-2358
pr@scorrmarketing.com